A novel, blood-based test developed using fragmentomic features of cell-free DNA (cfDNA) detects colorectal cancer (CRC) with a 90.4% sensitivity and shows consistent performance across stages and ...

Plasma cell-free DNA (cfDNA) is a promising biomarker for liquid biopsy, essential for diagnosing and monitoring diseases. Current methods for estimating tissue contributions primarily rely on ...

A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...

Pancreatic cancer is known for its lethal condition, with most cases being diagnosed at advanced stage. Recently, liquid biopsy has emerged as a promising tool in cancer detection. Here we develop ...

Researchers from Geneseeq and a network of Chinese academic hospitals have validated a blood test that can detect a broad range of cancers with high accuracy using cell-free DNA. A multi-cancer early ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...

DEAR DR. ROACH: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? -- M.N. ANSWER: When screening patients ...

Pediatric ENT infections are prevalent and one of the most common reasons for antibiotic prescriptions. Turnaround times of conventional culturing assays are long leading to poor clinical management ...

Tests that measure donor‑derived cell‑free DNA (dd‑cfDNA) are transforming how physicians monitor kidney transplant recipients, paving the way for earlier detection of graft injury. Further, the use ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Molecular Oncology comparing the performance of mean ...